Vaxcyte, Inc. (PCVX) stock

PCVXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30

$68.62+2.26 (+3.41%)

Close on Nov 11, 2026Market cap $10.21BP/E –Yield 0.00%

Vaxcyte gross margin

Gross margin is gross profit as a percentage of revenue.

Vaxcyte has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

See a number that looks wrong?